Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Link Technologies Announces Expansion into the Far East with New Distributor

Published: Thursday, June 13, 2013
Last Updated: Thursday, June 13, 2013
Bookmark and Share
Zirench Technology signed as local distributor for the Chinese market.

Link Technologies Ltd has announced Zirench Technology Co. Ltd as distributor in China, the first Asian distributor for its comprehensive range of products.

Located in Dalian City, Zirench Technology will represent Link Technologies in China, expanding their reach across the country and providing invaluable local support for customers.

The appointment of Zirench Technology is the first signing of multiple, upcoming distributorship agreements in the Far East, and is testament to Link Technologies’ on-going strategic development and growth.

As an ISO 9001:2008 certified supplier of products for oligonucleotide synthesis, Link Technologies is committed to providing all customers with high purity, reliable oligo precursors and reagents, which can now extend to customers in China, thanks to Zirench Technology.

Commenting on the new distributor agreement, Dr John Bremner, CEO at Link Technologies, said: “We are working hard to effectively deliver our products to customers in research and industrial institutions in Asia and other parts of the world, where easily accessible local support and expertise is very important. We are delighted that this deal with Zirench boosts this strategy.”

Dr Victor Liu, Commercial Manager at Zirench Technology, added “Our aim is to offer our customers laboratory instruments, supplies and biological agents of world-class quality. As such, we were keen to act on behalf of Link Technologies, to raise awareness of and distribute their high quality oligo precursor products across China.”

Providing a broad catalogue of reagents for DNA, RNA and PNA synthesis, Link Technologies has particular expertise in the manufacture of modified nucleic acid products, often unavailable elsewhere.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Link Technologies Inks Exclusive License to Agilent Technologies’ TC RNA Monomers
Under the terms of the agreement Link will manufacture and sell the four RNA monomer phosphoramidite reagents for use in research.
Monday, May 18, 2009
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
Testing Nanoparticle Drug Delivery in Dogs
Scientists have tested a nanoparticle drug delivery against bone cancer in dogs with promising results.
Fighting Cancer Through Protein Pathways
Researchers have found a new drug target within a protein production pathway critical to regulating growth and proliferation of cells.
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Exploiting Malaria’s Achilles’ Heel
Researchers have uncovered an Achilles' heel in malaria's anti-drug treatment arsenal that could lead to a disease cure.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!